MAPT and Cognitive impairment: Although a purely biological definition of AD has been proposed in the past, with the progress of research, an increasing number of studies have pointed out that amyloid P and Tau biomarkers are not enough to predict the progress of AD with confidence, nor are they enough to be applied to the clinical environment and diagnosis of people without cognitive impairment.